Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug candidate “foralumab” program entering ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback